» Articles » PMID: 2114389

Effect of Human Macrophage Colony-stimulating Factor on Granulopoiesis and Survival in Bone-marrow-transplanted Mice

Overview
Specialty Oncology
Date 1990 Apr 1
PMID 2114389
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Human macrophage colony-stimulating factor (hM-CSF) has been isolated from normal human urine and purified to a homogeneous protein. The effect of hM-CSF on granulopoiesis was investigated in BALB/c mice transplanted with a suboptimal number of bone marrow cells. Lethally irradiated (7.8 Gy) mice were transplanted with 1 x 10(6) syngeneic mouse bone marrow cells and treated with a daily intraperitoneal dose of 64 micrograms/kg of hM-CSF for 5 days following the transplant. The hM-CSF injection resulted in stimulation of the recovery of blood neutrophils as well as an increase in the number of granulocyte-macrophage progenitor cells (CFU-GM) in the femur and spleen. The survival of lethally irradiated mice was dependent on the cell number transplanted; most mice transplanted with 2 x 10(4) cells died within 2 weeks. The recovery of hematopoiesis in mice transplanted with 2 x 10(4) cells was modestly but significantly stimulated by hM-CSF administration initiated from 5 days before or 1 day after transplantation for a 5-day period. Furthermore, the hM-CSF administrations markedly reduced the mortality in these mice during the early period after the transplantation. Since anaerobic bacteria were frequently detected in arterial blood immediately before the deaths but were not found in the surviving mice, it is speculated that early deaths occurring within 2 weeks after the transplant may be caused by opportunistic infections, and hM-CSF injection may prevent these mortal infections through its stimulating effect on monocyte-macrophage functions that are responsible for the production of hematopoietic regulators.

Citing Articles

Antigen presenting cells treated in vitro by macrophage colony-stimulating factor and autoantigen protect mice from autoimmunity.

Guan Y, Yu S, Zhao Z, Ciric B, Zhang G, Rostami A J Neuroimmunol. 2007; 192(1-2):68-78.

PMID: 18006080 PMC: 2743086. DOI: 10.1016/j.jneuroim.2007.09.021.


A comparative review of colony-stimulating factors.

Nemunaitis J Drugs. 1997; 54(5):709-29.

PMID: 9360058 DOI: 10.2165/00003495-199754050-00004.


Augmentation of cancer chemotherapy by preinjection of human macrophage colony-stimulating factor in L1210 leukemic cell-inoculated mice.

Douzono M, Suzu S, Yamada M, Yanai N, Kawashima T, Hatake K Jpn J Cancer Res. 1995; 86(3):315-21.

PMID: 7538104 PMC: 5920809. DOI: 10.1111/j.1349-7006.1995.tb03057.x.

References
1.
Motoyoshi K, Takaku F, Miura Y . High serum colony-stimulating activity of leukocytopenic patients after intravenous infusions of human urinary colony-stimulating factor. Blood. 1983; 62(3):685-8. View

2.
Neta R, Douches S, Oppenheim J . Interleukin 1 is a radioprotector. J Immunol. 1986; 136(7):2483-5. View

3.
Dinarello C . Interleukin-1. Rev Infect Dis. 1984; 6(1):51-95. DOI: 10.1093/clinids/6.1.51. View

4.
Stork L, Peterson V, Rundus C, Robinson W . Interleukin-1 enhances murine granulopoiesis in vivo. Exp Hematol. 1988; 16(2):163-7. View

5.
Masaoka T, Motoyoshi K, Takaku F, Kato S, Harada M, Kodera Y . Administration of human urinary colony stimulating factor after bone marrow transplantation. Bone Marrow Transplant. 1988; 3(2):121-7. View